Radius Ready To Face Off With Amgen At ASBMR
This article was originally published in Scrip
Executive Summary
Conducting a large osteoporosis development program is a path that Amgen Inc. has been down before, but it's a make-or-break journey for Radius Health, which had one of the most successful initial public offerings during the recent biotechnology IPO boom based on optimism about its drug abaloparatide.
You may also be interested in...
Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
Merck’s COVID Manufacturing Deal With US Government Goes Well Beyond J&J Vaccine
‘Wartime’ contract with BARDA will fund up to $268.8m in production site upgrades so Merck can also produce other COVID-19 vaccines and therapeutics as needed.
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: